BCRX Summary

  1. NASDAQ
  2. >
  3. BCRX
TickerBCRX
DescriptionBIOCRYST PHARMACEUTICALS INC
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Employees246
Next Earnings DateAugust 5th, 2021
IV84.005746%
IV Percentile25th
IV Rank5.99%
IV Skew4.460588
IV Skew Percentile67th
IV Skew SentimentBearish
Option Volume8,245
Volume1,186,882
Price$16.47
Previous Close$16.76
52-Week High$17.735
52-Week Low$3.30
50-Day Moving Avg.$16.32
200-Day Moving Avg.$13.00
10-Day Avg. Volume2,074,713
20-Day Avg. Volume2,295,550
30-Day Avg. Volume2,309,675
3-Month Avg. Volume3,541,741
EPS-$1.21
Outstanding Shares177,696,474
Market Capitalization$2,860,913,200
CurrencyUSD
UpdatedAugust 4th, 2021